 Fennec Pharmaceuticals Inc. FENC FRX.TO, a specialty pharmaceutical company focused on the development of PEDMARKTM a unique formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity from cisplatin in pediatric cancer patients, today announced that in connection with its previously completed underwritten offering on May 4, 2020 of 30,000,000 at a price of 6.25 per share, the option granted to the underwriters was exercised for 660,204 shares at a price of 6.25 per share for additional gross proceeds of 4,126,275. Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development of PEDMARKTM for the prevention of platinum-induced ototoxicity in pediatric patients. 